EDP installs solar panels at Singapore’s Gardens by the Bay under new agreement

Vera Pinto Pereira Member of the Executive Board of Directors EDP - Energias de Portugal SA
Vera Pinto Pereira Member of the Executive Board of Directors - EDP - Energias de Portugal SA
0Comments

Gardens by the Bay in Singapore has completed the installation of a new solar photovoltaic system through a partnership with EDP, implemented by EDP Renewables APAC under a Power Purchase Agreement. The expanded system consists of more than 1,700 solar panels and delivers a total capacity of 1.08MWp. This initiative aims to supply part of the energy needs for Gardens by the Bay’s operations while advancing its sustainability goals.

The new infrastructure covers several areas across Gardens by the Bay, including Supertree Grove as well as new locations such as the Canopy and Bayfront Pavilion. The project demonstrates EDP’s ability to design renewable energy solutions that address space constraints typical in urban environments.

EDP collaborated closely with Gardens by the Bay throughout the project, using specialized installation designs to maximize solar output on unique surfaces. For example, installing panels on the Supertrees presented technical challenges due to their irregular shapes, requiring tailored approaches to maintain safety and preserve both plant life and visual aesthetics.

Vera Pinto Pereira, EDP’s board member, stated: “This project at Gardens by the Bay is a clear example of how to harness the sun wherever it shines — from rooftops and open ground to the iconic Supertrees that shape Singapore’s skyline. By combining innovation, tailored design, and close collaboration with our clients, we can transform even the most unconventional spaces into sources of clean energy. In a land-constrained city, every surface has the potential to contribute to decarbonization, and this initiative reflects our commitment to delivering smart, scalable solutions that help our partners achieve their long-term sustainability goals.”

Gardens by the Bay is recognized for its emphasis on environmental sustainability since opening in 2012. The attraction features more than 1.5 million plants from various climates and habitats and has welcomed over 100 million visitors.

EDP operates internationally across Europe, North America, South America, and Asia Pacific. With approximately 12,000 employees worldwide and more than 32 GW of installed renewable generation capacity—including wind (onshore/offshore), solar, and hydro—EDP continues investing in technologies like green hydrogen and grid expansion as part of its transition strategy toward cleaner energy sources.

As one of the largest producers of renewable energy globally, EDP generates over 90% of its electricity from renewables. It plans to invest more than €14 billion into expanding renewable capacity and strengthening electricity networks by 2026.

In Asia Pacific alone, EDP reports having over 1.6 GWp of committed renewables capacity as of mid-2025. The company’s regional headquarters are located in Singapore where it pursues access to clean energy for APAC markets.



Related

Paul Hudson Chief Executive Officer Sanofi SA

Acoziborole receives key EU panel backing as single-dose treatment for sleeping sickness

Acoziborole Winthrop, a new oral treatment for sleeping sickness developed by the Drugs for Neglected Diseases initiative (DNDi) and Sanofi, has received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for…

Martin Lundstedt President and CEO at Volvo Group North America LLC Volvo Group North America LLC

Volvo announces updated share and vote count after series conversion

The number of votes in AB Volvo has changed following the conversion of 2,000,619 Series A shares into an equal number of Series B shares.

Paul Hudson Chief Executive Officer Sanofi SA

Sanofi and Regeneron’s Dupixent recommended for EU approval in young children with chronic urticaria

Sanofi and Regeneron have announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending approval of Dupixent (dupilumab) for children aged two to 11 years with…

Trending

The Weekly Newsletter

Sign-up for the Weekly Newsletter from EU Business Daily.